Compare Grab Holdings Ltd. (GRAB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Sanofi SA — how do they compare? Grab Holdings Ltd. trades at $3.65 (market cap $15.26B), while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 6.8× Grab Holdings Ltd.'s market cap, and Sanofi SA pays a 5.55% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | SNY | |
|---|---|---|
Market Cap | $15.26B | $104.30B |
Sector | Technology | Health |
52-Week High | $6.45 | $52.34 |
52-Week Low | $3.27 | $41.33 |
Enterprise Value | $10.99B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.67, up 0.27% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance after Q2 results, driven by on-demand and financial services growth. Analyst consensus is strongly bullish with an average price target of $5.86, implying 58% upside.
The outlook is positive given consistent earnings outperformance and raised guidance, but risks include high valuation (P/E 34), insider selling, and projected negative cash flow in 2026. Investors should weigh growth momentum against execution challenges in competitive Southeast Asian markets.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
